Accepted Articles
Back to the articles list |
Back to browse issues page
1- Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Institute for Cognitive and Brain Sciences, Shahid Beheshti University, Tehran, Iran
3- Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran & Behavioral Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Institute for Cognitive and Brain Sciences, Shahid Beheshti University, Tehran, Iran
3- Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran & Behavioral Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
Objective: This study aims to compare the efficacy of three common Selective Serotonin Reuptake Inhibitors (SSRIs)—fluoxetine, fluvoxamine, and sertraline—in treating anxiety disorders, major depressive disorder, and obsessive-compulsive disorder (OCD).
Methods: This eight-week randomized controlled clinical trial included 90 participants who were randomly assigned to receive either fluoxetine (20 mg), fluvoxamine (150 mg), or sertraline (100 mg). Symptom severity was assessed at baseline and after treatment using the Beck Anxiety Inventory (BAI), Beck Depression Inventory-II (BDI-II), and the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).
Results: The results indicated that all three medications significantly reduced symptoms of anxiety, depression, and OCD (p<0.05). However, a one-way ANOVA showed no statistically significant difference among the efficacies of the three drugs in reducing scores on any of the assessment scales.
Conclusions: While fluoxetine, fluvoxamine, and sertraline were all effective, none demonstrated superior efficacy over the others. The choice of medication should therefore be based on considerations such as side effect profiles, drug interactions, cost, and patient-specific characteristics.
Methods: This eight-week randomized controlled clinical trial included 90 participants who were randomly assigned to receive either fluoxetine (20 mg), fluvoxamine (150 mg), or sertraline (100 mg). Symptom severity was assessed at baseline and after treatment using the Beck Anxiety Inventory (BAI), Beck Depression Inventory-II (BDI-II), and the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).
Results: The results indicated that all three medications significantly reduced symptoms of anxiety, depression, and OCD (p<0.05). However, a one-way ANOVA showed no statistically significant difference among the efficacies of the three drugs in reducing scores on any of the assessment scales.
Conclusions: While fluoxetine, fluvoxamine, and sertraline were all effective, none demonstrated superior efficacy over the others. The choice of medication should therefore be based on considerations such as side effect profiles, drug interactions, cost, and patient-specific characteristics.
Type of Study: Original |
Subject:
Cognitive Neuroscience
Received: 2025/06/16 | Accepted: 2025/11/2
Received: 2025/06/16 | Accepted: 2025/11/2
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
